Posted by Michael Wonder on 14 Sep 2020
Will Tagrisso win insurance benefits in Korea, too?
14 September 2020 - AstraZeneca’s Tagrisso, targeted therapy for lung cancer, has won recognition as the first-line standard treatment for epidermal growth factor receptor mutated lung cancer in the U.K., Taiwan, and Australia.
The latest development has drawn attention to whether the Korean authorities would allow the national health insurance benefit for Tagrisso, observers said.
